BACKGROUND: L-Buthionine (S,R) sulfoximine (BSO) is an inhibitor of glutathione biosynthesis and has been used as an effective means of depleting glutathione from cells and tissues. Here we investigated whether treatment with BSO enhanced ethanol-induced liver injury in mice. METHODS: Female C57Bl/6 mice were pair fed with control and ethanol-containing liquid diets in which ethanol was 29.2% of total calories. During the final 7 days of pair feeding, groups of control-fed and ethanol-fed mice were given 0, 5 or 7.6 mM BSO in the liquid diets. RESULTS: Compared with controls, ethanol given alone decreased total liver glutathione. This effect was exacerbated in mice given ethanol with 7.6 mM BSO, causing a 72% decline in hepatic glutathione. While ethanol alone caused no decrease in mitochondrial glutathione, inclusion of 7.6 mM BSO caused a 2-fold decline compared with untreated controls. L-Buthionine (S,R) sulfoximine did not affect ethanol consumption, but serum ethanol levels in BSO-treated mice were nearly 6-fold lower than in mice given ethanol alone. The latter decline in serum ethanol was associated with a significant elevation in the specific activities of cytochrome P450 2E1 and alcohol dehydrogenase in livers of BSO-treated animals. Ethanol consumption caused a 3.5-fold elevation in serum alanine aminotransferase levels but the enzyme fell to control levels when BSO was included in the diet. L-Buthionine (S,R) sulfoximine administration also attenuated ethanol-induced steatosis, prevented the leakage of lysosomal cathepsins into the cytosol, and prevented the ethanol-elicited decline in proteasome activity. CONCLUSIONS: L-Buthionine (S,R) sulfoximine, administered with ethanol, significantly depleted hepatic glutathione, compared with controls. However, despite the decrease in hepatic antioxidant levels, liver injury by ethanol was alleviated, due, in part, to a BSO-elicited acceleration of ethanol metabolism.
BACKGROUND:L-Buthionine(S,R) sulfoximine (BSO) is an inhibitor of glutathione biosynthesis and has been used as an effective means of depleting glutathione from cells and tissues. Here we investigated whether treatment with BSO enhanced ethanol-induced liver injury in mice. METHODS: Female C57Bl/6 mice were pair fed with control and ethanol-containing liquid diets in which ethanol was 29.2% of total calories. During the final 7 days of pair feeding, groups of control-fed and ethanol-fed mice were given 0, 5 or 7.6 mM BSO in the liquid diets. RESULTS: Compared with controls, ethanol given alone decreased total liver glutathione. This effect was exacerbated in mice given ethanol with 7.6 mM BSO, causing a 72% decline in hepatic glutathione. While ethanol alone caused no decrease in mitochondrial glutathione, inclusion of 7.6 mM BSO caused a 2-fold decline compared with untreated controls. L-Buthionine(S,R) sulfoximine did not affect ethanol consumption, but serum ethanol levels in BSO-treated mice were nearly 6-fold lower than in mice given ethanol alone. The latter decline in serum ethanol was associated with a significant elevation in the specific activities of cytochrome P450 2E1 and alcohol dehydrogenase in livers of BSO-treated animals. Ethanol consumption caused a 3.5-fold elevation in serum alanine aminotransferase levels but the enzyme fell to control levels when BSO was included in the diet. L-Buthionine(S,R) sulfoximine administration also attenuated ethanol-induced steatosis, prevented the leakage of lysosomal cathepsins into the cytosol, and prevented the ethanol-elicited decline in proteasome activity. CONCLUSIONS:L-Buthionine(S,R) sulfoximine, administered with ethanol, significantly depleted hepatic glutathione, compared with controls. However, despite the decrease in hepatic antioxidant levels, liver injury by ethanol was alleviated, due, in part, to a BSO-elicited acceleration of ethanol metabolism.
Authors: Terrence M Donohue; Natalia A Osna; Casey S Trambly; Nash P Whitaker; Paul G Thomes; Sandra L Todero; John S Davis Journal: Alcohol Clin Exp Res Date: 2011-12-05 Impact factor: 3.455
Authors: Robin M Voigt; Christopher B Forsyth; Maliha Shaikh; Lijuan Zhang; Shohreh Raeisi; Costica Aloman; Nailliw Z Preite; Terrence M Donohue; Louis Fogg; Ali Keshavarzian Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-10-26 Impact factor: 4.052
Authors: Natalia A Osna; Fawzia Bardag-Gorce; Ronda L White; Steven A Weinman; Terrence M Donohue; Kusum K Kharbanda Journal: Alcohol Clin Exp Res Date: 2012-05-02 Impact factor: 3.455
Authors: Andre L Wimberly; Christopher B Forsyth; Mohammad W Khan; Alan Pemberton; Khashayarsha Khazaie; Ali Keshavarzian Journal: Alcohol Clin Exp Res Date: 2013-01 Impact factor: 3.455
Authors: Blair U Bradford; Thomas M O'Connell; Jun Han; Oksana Kosyk; Svitlana Shymonyak; Pamela K Ross; Jason Winnike; Hiroshi Kono; Ivan Rusyn Journal: Toxicol Appl Pharmacol Date: 2008-07-12 Impact factor: 4.219
Authors: Christopher B Forsyth; Robin M Voigt; Maliha Shaikh; Yueming Tang; Arthur I Cederbaum; Fred W Turek; Ali Keshavarzian Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-05-09 Impact factor: 4.052
Authors: Keith C Summa; Robin M Voigt; Christopher B Forsyth; Maliha Shaikh; Kate Cavanaugh; Yueming Tang; Martha Hotz Vitaterna; Shiwen Song; Fred W Turek; Ali Keshavarzian Journal: PLoS One Date: 2013-06-18 Impact factor: 3.240